Briacell Therap Stock Set to Reverse Split on Tuesday, August 26th (NASDAQ:BCTX)

Briacell Therap (NASDAQ:BCTX)’s stock is going to reverse split on the morning of Tuesday, August 26th. The 1-10 reverse split was announced on Tuesday, August 5th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, August 25th.

Briacell Therap Trading Up 0.1%

Shares of NASDAQ BCTX opened at $0.74 on Monday. Briacell Therap has a 12 month low of $0.61 and a 12 month high of $29.40. The firm has a market capitalization of $5.02 million, a price-to-earnings ratio of -0.09 and a beta of 1.07. The business has a 50-day moving average of $1.89 and a 200-day moving average of $3.21.

Briacell Therap (NASDAQ:BCTX) last issued its quarterly earnings data on Friday, June 13th. The company reported ($1.64) EPS for the quarter, topping the consensus estimate of ($1.76) by $0.12. On average, analysts predict that Briacell Therap will post -2.45 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of Briacell Therap in a research note on Tuesday, April 22nd.

Institutional Trading of Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Cantor Fitzgerald L. P. bought a new position in Briacell Therap (NASDAQ:BCTX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 56,000 shares of the company’s stock, valued at approximately $32,000. Cantor Fitzgerald L. P. owned approximately 1.90% of Briacell Therap at the end of the most recent reporting period. Institutional investors own 15.42% of the company’s stock.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.